Lung transplantation for cystic fibrosis.
Lung transplantation currently stands as the only therapeutic option that carries the potential to restore patients with advanced cystic fibrosis to a more normal state of health. Nonetheless, the procedure carries significant risk and median survival following transplantation is only 5 years. This article discusses the currently achievable outcomes and the common short-comings of transplantation. Strategies to optimize outcomes through appropriate patient selection, use of living donors, and novel research initiatives are discussed.
Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, USA.
J B
JB
Zuckerman
R M
RM
Kotloff
D003550:Cystic Fibrosis / Q000150:complications / Q000382:microbiology / Q000503:physiopathology / Q000601:surgery*; D048909:Diabetes Complications; D017079:Exercise Tolerance; D006084:Graft Rejection; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications; D019520:Living Donors; D016040:Lung Transplantation / Q000706:statistics & numerical data; D009747:Nutritional Physiological Phenomena; D010024:Osteoporosis / Q000150:complications; D018579:Patient Selection; D011788:Quality of Life; D012121:Respiration, Artificial; D016896:Treatment Outcome